Cargando…

Antimicrobial activity of ceftobiprole and comparator agents when tested against gram-positive and -negative organisms collected across China (2016–2018)

BACKGROUND: Ceftobiprole is a fifth-generation cephalosporin which has been reported to have broad antibacterial spectrum when tested against bacteria collected from other countries except China. This study evaluated the in vitro activity of ceftobiprole in comparison with other comparators against...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dandan, Yin, Shi, Wu, Yang, Yang, Yonggui, Zheng, Zhu, Demei, Yan, Guo, Hu, Fupin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701444/ https://www.ncbi.nlm.nih.gov/pubmed/36435810 http://dx.doi.org/10.1186/s12866-022-02699-4

Ejemplares similares

In Vitro Activity of MRX-8 and Comparators Against Clinical Isolated Gram-Negative Bacilli in China
por: Wu, Shi, et al.
Publicado: (2022)

Mechanisms of action and antimicrobial activity of ceftobiprole
por: Morosini, María-Isabel, et al.
Publicado: (2019)

Ceftobiprole Activity When Tested Against Contemporary Bacteria Causing Bloodstream Infections in the US (2016)
por: Flamm, Robert K, et al.
Publicado: (2017)

In Vitro Activity of New β-Lactam–β-Lactamase Inhibitor Combinations and Comparators against Clinical Isolates of Gram-Negative Bacilli: Results from the China Antimicrobial Surveillance Network (CHINET) in 2019
por: Guo, Yan, et al.
Publicado: (2022)

Ceftobiprole medocaril
por: Méndez, Raúl, et al.
Publicado: (2022)

576. A Multicenter Epidemiology Study on Risk Factors of Vancomycin-Resistant Enterococcus Infections in China: Results from the China Antimicrobial Surveillance Network (CHINET) in 2016
por: Lin, Dongfang, et al.
Publicado: (2019)

697. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06)
por: Yang, Yang, et al.
Publicado: (2019)

1595. Ceftobiprole Activity against Gram-Positive Pathogens Causing Bone and Joint Infections in the United States from 2016 through 2019
por: Duncan, Leonard R, et al.
Publicado: (2020)

2162. In Vitro Antimicrobial Activity of Ceftobiprole against Streptococcus pneumoniae Isolates from the United States (2016–2020)
por: Duncan, Leonard R, et al.
Publicado: (2023)

Novel Antimicrobial Agents for Gram-Negative Pathogens
por: Karvouniaris, Marios, et al.
Publicado: (2023)

In vitro Activity of Lefamulin Against the Common Respiratory Pathogens Isolated From Mainland China During 2017–2019
por: Wu, Shi, et al.
Publicado: (2020)

Safety and tolerability of ceftobiprole
por: Grau, Santiago
Publicado: (2019)

Ceftobiprole for the treatment of pneumonia
por: Cillóniz, Catia, et al.
Publicado: (2019)

2478. Surveillance of antibacterial resistance among clinical isolates from hospitals in Shanghai: results of 2018
por: Yang, Yang, et al.
Publicado: (2019)

Emerging agents to combat complicated and resistant infections: focus on ceftobiprole
por: Bustos, César, et al.
Publicado: (2010)

Possible clinical indications of ceftobiprole
por: Barberán, José
Publicado: (2019)

Ceftobiprole: a clinical view
por: Pérez-Crespo, Pedro María Martínez, et al.
Publicado: (2021)

Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial
por: Zhang, Zhijie, et al.
Publicado: (2018)

In vitro activity of ceftobiprole and comparator antibiotics against contemporary European isolates (2016–19)
por: Canton, Rafael, et al.
Publicado: (2022)

1240. Ceftobiprole Activity against Drug-Resistant Staphylococcus aureus Clinical Isolates Collected in the United States from 2016 through 2020
por: Duncan, Leonard R, et al.
Publicado: (2021)

Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria
por: Taneja, Neelam, et al.
Publicado: (2016)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients
por: Rubino, Christopher M., et al.
Publicado: (2021)

Assessment of Ceftazidime-Avibactam 30/20-μg Disk, Etest versus Broth Microdilution Results When Tested against Enterobacterales Clinical Isolates
por: Han, Renru, et al.
Publicado: (2022)

Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014–2015
por: Santerre Henriksen, Anne, et al.
Publicado: (2018)

Ceftobiprole for the treatment of pneumonia: a European perspective
por: Liapikou, Adamantia, et al.
Publicado: (2015)

Ceftobiprole Perspective: Current and Potential Future Indications
por: Lupia, Tommaso, et al.
Publicado: (2021)

Characterization of carbapenem-resistant gram-negative bacteria collected in the Sentinel Surveillance Program, 2018–2019
por: Spicer, Lori, et al.
Publicado: (2022)

1946. In Vitro Activity of Ceftobiprole against Staphylococcus aureus Bacteremia Isolates from the United States (2018–2020)
por: Duncan, Leonard R, et al.
Publicado: (2023)

Motuporamine Derivatives as Antimicrobial Agents and Antibiotic Enhancers against Resistant Gram‐Negative Bacteria
por: Borselli, Diane, et al.
Publicado: (2017)

In Vitro Activity of Tedizolid, Dalbavancin, and Ceftobiprole Against Clostridium difficile
por: Binyamin, Dana, et al.
Publicado: (2018)

Pharmacokinetics and Target Attainment of Ceftobiprole in Asian and Non‐Asian Subjects
por: Muller, A. E., et al.
Publicado: (2018)

Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric Patients
por: Rubino, Christopher M., et al.
Publicado: (2021)

Klebsiella pneumoniae: Development of Carbapenem Resistance due to Acquisition of bla(NDM-1) During Antimicrobial Therapy in Twin Infants with Pneumonia
por: Zhu, Junying, et al.
Publicado: (2015)

The Immunomodulatory Drug Glatiramer Acetate is Also an Effective Antimicrobial Agent that Kills Gram-negative Bacteria
por: Christiansen, Stig Hill, et al.
Publicado: (2017)

Mechanisms of antimicrobial resistance in Gram-negative bacilli
por: Ruppé, Étienne, et al.
Publicado: (2015)

Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013–2015
por: Henriksen, Anne Santerre, et al.
Publicado: (2018)

Combination Regimens with Colistin Sulfate versus Colistin Sulfate Monotherapy in the Treatment of Infections Caused by Carbapenem-Resistant Gram-Negative Bacilli
por: Hao, Min, et al.
Publicado: (2022)

Pharmacokinetic-pharmacodynamic profiling of four antimicrobials against Gram-negative bacteria collected from Shenyang, China
por: Chu, Yun Zhuo, et al.
Publicado: (2010)

Long-Term Continuous Antimicrobial Resistance Surveillance Among Nosocomial Gram-Negative Bacilli in China from 2010 to 2018 (CMSS)
por: Wang, Qi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_58rs43lrquasjb6a2bt4qifvqu